References
- Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90. https://doi.org/10.1056/NEJMoa0708857
- Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, doubleblind, placebo-controlled trial. Lancet Oncol 2009;10:25-34. https://doi.org/10.1016/S1470-2045(08)70285-7
- Robert C, Mateus C, Spatz A, Wechsler J, Escudier B. Dermatologic symptoms associated with the multikinase inhibitor sorafenib. J Am Acad Dermatol 2009;60:299-305. https://doi.org/10.1016/j.jaad.2008.06.034
- Camidge R, Price A. Characterizing the phenomenon of radiation recall dermatitis. Radiother Oncol 2001;59:237-45. https://doi.org/10.1016/S0167-8140(01)00328-0
- Chung C, Dawson LA, Joshua AM, Brade AM. Radiation recall dermatitis triggered by multi-targeted tyrosine kinase inhibitors: sunitinib and sorafenib. Anticancer Drugs 2010;21:206-9. https://doi.org/10.1097/CAD.0b013e328333d679
- Hymes SR, Strom EA, Fife C. Radiation dermatitis: clinical presentation, pathophysiology, and treatment 2006. J Am Acad Dermatol 2006;54:28-46. https://doi.org/10.1016/j.jaad.2005.08.054
- Yang CH, Lin WC, Chuang CK, et al. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol 2008;158:592-6.
- D'Angio GJ, Farber S, Maddock CL. Potentiation of X-ray effects by actinomycin D. Radiology 1959;73:175-7.
- Hird AE, Wilson J, Symons S, Sinclair E, Davis M, Chow E. Radiation recall dermatitis: case report and review of the literature. Curr Oncol 2008;15:53-62. https://doi.org/10.3747/co.2008.201
- Law AB, Junor EJ. Chemotherapy-induced recall of cetuximab and radiation skin reaction. Clin Oncol (R Coll Radiol) 2009;21:77-8. https://doi.org/10.1016/j.clon.2008.11.001
- Chung C, Stuart D, Keyes M. Radiation recall reaction induced by adjuvant trastuzumab (herceptin). Case Report Med 2009;2009:307894.
- Shrimali RK, McPhail NJ, Correa PD, Fraser J, Rizwanullah M. Trastuzumab-induced radiation recall dermatitis: first reported case. Clin Oncol (R Coll Radiol) 2009;21:634-5. https://doi.org/10.1016/j.clon.2009.03.003
- Bostrom A, Sjolin-Forsberg G, Wilking N, Bergh J. Radiation recall: another call with tamoxifen. Acta Oncol 1999;38:955-9. https://doi.org/10.1080/028418699432653
- Azria D, Magne N, Zouhair A, et al. Radiation recall: a well recognized but neglected phenomenon. Cancer Treat Rev 2005;31:555-70. https://doi.org/10.1016/j.ctrv.2005.07.008
Cited by
- Sorafenib : Radiation recall dermatitis and disseminated exanthematous rash: case report vol.1478, pp.1, 2013, https://doi.org/10.1007/s40278-013-7243-z
- Recall radiation dermatitis by sorafenib following stereotactic body radiation therapy vol.7, pp.None, 2013, https://doi.org/10.2147/ott.s64706
- Radiation recall dermatitis induced by sorafenib : A case study and review of the literature vol.192, pp.5, 2016, https://doi.org/10.1007/s00066-016-0950-7
- Nodular-cystic eruption in course of sorafenib administration for hepatocarcinoma: An unconventional skin reaction requiring unconventional treatment vol.30, pp.3, 2017, https://doi.org/10.1177/0394632017727618
- Radiation recall dermatitis triggered by sorafenib after radiation therapy for hepatocellular carcinoma vol.35, pp.3, 2013, https://doi.org/10.3857/roj.2017.00339
- Reacciones cutáneas a fármacos en el paciente con leucemia/linfoma vol.32, pp.9, 2013, https://doi.org/10.1016/j.piel.2017.01.010
- Radiation Recall Dermatitis in Patients Treated with Sorafenib vol.2018, pp.None, 2013, https://doi.org/10.1155/2018/2171062
- Hematuria induced by combination regorafenib and hyperthermia - a radiation recall effect vol.36, pp.1, 2013, https://doi.org/10.1080/02656736.2019.1687941
- Spine stereotactic radiosurgery for metastatic thyroid cancer: a single-institution experience vol.32, pp.6, 2020, https://doi.org/10.3171/2019.12.spine191269
- Spine stereotactic radiosurgery for metastatic thyroid cancer: a single-institution experience vol.32, pp.6, 2020, https://doi.org/10.3171/2019.12.spine191269